Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9114925 | 0.87 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL9112258 | 0.82 | ALOX15 (0.38) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL8955182 | 0.80 | ALOX15 (0.32) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL161929 | 0.79 | ARG1 (0.47) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL6431682 | 0.79 | ARG1 (0.47) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL202490 | 0.79 | ARG1 (0.47) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL263015 | 0.79 | ALOX15 (0.40) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11674300 | 0.78 | ARG1 (0.46) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11674295 | 0.78 | ARG1 (0.46) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL19686889 | 0.77 | ALOX15 (0.36) | ALOX15MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967219-B2 | Reversing or preventing premature vascular senescence | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6784178-B2 | ADMINISTERING TO THE PATIENT AN ENDOTHELIAL DYSFUNCTION REVERSING OR DIMINISHING EFFECTIVE AMOUNT OF AN AGENT WHICH IS SELECTED FROM THE GROUP CONSISTING OF NITRIC OXIDE BIOACTIVITY INCREASING HYDROXYGUANIDINES AND SALTS | CORNELL RESEARCH FOUNDATION, INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1441712-A2 | REVERSING OR PREVENTING PREMATURE VASCULAR SENESCENCE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030212135-A1 | Pharmacotherapy for vascular dysfuntion associated with deficient nitric oxide bioactivity | GROSS STEVEN S (US) | 2003-11-13 | — | — | US | disclosed |
| WO-2003032804-A2 | REVERSING OR PREVENTING PREMATURE VASCULAR SENESCENCE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| US-20030073747-A1 | Reversing or preventing premature vascular senescence | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212135-A1 | Pharmacotherapy for vascular dysfuntion associated with deficient nitric oxide bioactivity | NOS1, NOS2, NOS3 | ALOX15 204/4885MEN1 2625/4885CYP1A2 1235/4885 |
| US-20030073747-A1 | Reversing or preventing premature vascular senescence | AGER, GLA, POT1 | ALOX15 1264/4885MEN1 2926/4885CYP1A2 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.